Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Bendstrup

Showing results (161-170 of 216) with videos related to

Pageof 22
Sort By:
The European Respiratory Journal|February 2, 2018
Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trialIngeborg Farver-Vestergaard, Mia S O'Toole, Maja O'Connor, et al.
European Clinical Respiratory Journal|January 18, 2021
An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettesKarin Rosenkilde Laursen, Jakob Hjort Bønløkke, Elisabeth Bendstrup, et al.
BMC Pulmonary Medicine|November 24, 2021
Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosisHenrik Jessen, Nils Hoyer, Thomas S Prior, et al.
Respiratory Medicine|April 5, 2026
Elexacaftor/tezacaftor/ivacaftor is safe and effectively reduces sino-nasal symptoms in people with cystic fibrosis post lung transplantationInger Hee Mazuba Mathiesen, Frederikke Falkencrone Rönsholt, Kasper Aanæs, et al.
Respiratory Research|June 27, 2023
Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational studyPeter Kamstrup, Pradeesh Sivapalan, Christian Rønn, et al.
Ugeskrift for Laeger|October 3, 2018
[Treatment limitations or discontinuation in patients with benign pulmonary diseases]Anita Rath Sørensen, Elisabeth Bendstrup, Anders Løkke, et al.
The Lancet. Respiratory Medicine|May 11, 2016
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trialJürgen Behr, Elisabeth Bendstrup, Bruno Crestani, et al.
Respirology (Carlton, Vic.)|April 9, 2021
High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosisNils Hoyer, Henrik Jessen, Thomas S Prior, et al.
Journal of Clinical Medicine|April 3, 2021
Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational StudyJesper Rømhild Davidsen, Christian B Laursen, Mikkel Højlund, et al.
Respiration; International Review of Thoracic Diseases|December 13, 2019
Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic DiseaseWim A Wuyts, Marlies Wijsenbeek, Benjamin Bondue, et al.
Pageof 22

Showing results (161-170 of 216) with videos related to

Sort By:
Pageof 22
The European Respiratory Journal|February 2, 2018
Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trialIngeborg Farver-Vestergaard, Mia S O'Toole, Maja O'Connor, et al.
European Clinical Respiratory Journal|January 18, 2021
An RCT of acute health effects in COPD-patients after passive vape exposure from e-cigarettesKarin Rosenkilde Laursen, Jakob Hjort Bønløkke, Elisabeth Bendstrup, et al.
BMC Pulmonary Medicine|November 24, 2021
Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosisHenrik Jessen, Nils Hoyer, Thomas S Prior, et al.
Respiratory Medicine|April 5, 2026
Elexacaftor/tezacaftor/ivacaftor is safe and effectively reduces sino-nasal symptoms in people with cystic fibrosis post lung transplantationInger Hee Mazuba Mathiesen, Frederikke Falkencrone Rönsholt, Kasper Aanæs, et al.
Respiratory Research|June 27, 2023
Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational studyPeter Kamstrup, Pradeesh Sivapalan, Christian Rønn, et al.
Ugeskrift for Laeger|October 3, 2018
[Treatment limitations or discontinuation in patients with benign pulmonary diseases]Anita Rath Sørensen, Elisabeth Bendstrup, Anders Løkke, et al.
The Lancet. Respiratory Medicine|May 11, 2016
Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trialJürgen Behr, Elisabeth Bendstrup, Bruno Crestani, et al.
Respirology (Carlton, Vic.)|April 9, 2021
High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosisNils Hoyer, Henrik Jessen, Thomas S Prior, et al.
Journal of Clinical Medicine|April 3, 2021
Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational StudyJesper Rømhild Davidsen, Christian B Laursen, Mikkel Højlund, et al.
Respiration; International Review of Thoracic Diseases|December 13, 2019
Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic DiseaseWim A Wuyts, Marlies Wijsenbeek, Benjamin Bondue, et al.
Pageof 22